 |
|
Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
Hyun Jin Oh (Oh HJ), Mun Sung Cho (Cho MS), Jae Wook Lee (Lee JW), Pil-Sang Jang (Jang PS), Nack-Gyun Chung (Chung NG), Bin Cho (Cho B), Hack-Ki Kim (Kim HK)
Clin Exp Pediatr. 2013;56(8):343-350. Published online 2013 Aug 27 DOI: https://doi.org/10.3345/kjp.2013.56.8.343
|
|
Citations to this article as recorded by
 Cases of Patients Treated in Countries With Limited Resources and Discussed by Experts of the International CML Foundation (iCMLf)—Case No. 2: Treatment‐Free Remission After 9 Years of Imatinib Treatment Without Prior Achievement of Sustained Deep Molecul
Mariana Bohns Michalowski, Meinolf Suttorp, Arlene Harriss-Buchan, Guiseppe Saglio, Nicola Evans, Nirmalya Roy Moulik, Jose I. Mayordomo
Case Reports in Oncological Medicine.2025;[Epub] CrossRef Neuro-ophthalmic complications of modern anti-cancer drugs
Joshua A. Oskam, Helen V. Danesh-Meyer
Graefe's Archive for Clinical and Experimental Oph.2024; 262(7): 2269. CrossRef Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas
Ioannis Kyriakidis, Elpis Mantadakis, Eftichia Stiakaki, Andreas H. Groll, Athanasios Tragiannidis
Cancers.2022; 14(20): 5022. CrossRef Horn of plenty: Value of the international registry for pediatric chronic myeloid leukemia
Meinolf Suttorp, Markus Metzler, Frédéric Millot
World Journal of Clinical Oncology.2020; 11(6): 308. CrossRef Optimal management for pediatric chronic myeloid leukemia
Akihiko Tanizawa
Pediatrics International.2016; 58(3): 171. CrossRef Leucémie myéloïde chronique des sujets jeunes : expérience dans une unité d’hématologie clinique au Sénégal
S. Fall, F.S.D. Ndiaye, O.D. Dior, A.F. Sall, I. Sloma, A. Touré-Fall, Y. Keita
Revue d'Oncologie Hématologie Pédiatrique.2015; 3(4): 170. CrossRef
|